We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aptamer Group Plc | LSE:APTA | London | Ordinary Share | GB00BNRRP542 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.285 | 6,637,466 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.27 | 0.30 | 0.285 | 0.285 | 0.285 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 860k | -2.96M | -0.0015 | -1.87 | 5.47M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:09:16 | O | 1,670 | 0.30 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 29/11/2024 | 11:05 | UK RNS | Aptamer Group PLC Results of 2024 Annual General Meeting |
| 29/11/2024 | 07:00 | UK RNS | Aptamer Group PLC AGM Statement |
| 07/11/2024 | 07:00 | UK RNS | Aptamer Group PLC Agreement extended with genetic medicines customer |
| 06/11/2024 | 07:00 | UK RNS | Aptamer Group PLC Commercial Trading Update |
| 05/11/2024 | 07:00 | UK RNS | Aptamer Group PLC Posting of Annual Report and Notice of AGM |
| 22/10/2024 | 06:00 | UK RNS | Aptamer Group PLC Full Year Results for the 12mths to 30 June 2024 |
| 17/10/2024 | 06:00 | UK RNS | Aptamer Group PLC Notice of Results and Investor Presentation |
| 16/9/2024 | 06:00 | UK RNS | Aptamer Group PLC Director Appointment |
| 03/9/2024 | 10:05 | ALNC |  Aptamer Group extends Optimer development contract with Unilever |
| 03/9/2024 | 06:00 | UK RNS | Aptamer Group PLC Aptamer extends contract with Unilever |
Aptamer (APTA) Share Charts1 Year Aptamer Chart |
|
1 Month Aptamer Chart |
Intraday Aptamer Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/12/2024 | 13:06 | ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ | 5,463 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:09:17 | 0.30 | 1,670 | 5.01 | O |
| 15:59:40 | 0.28 | 100,000 | 280.00 | O |
| 15:53:46 | 0.27 | 400,440 | 1,087.88 | O |
| 15:38:51 | 0.30 | 463 | 1.39 | O |
| 14:58:53 | 0.27 | 1,000,000 | 2,745.00 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Aptamer Daily Update Aptamer Group Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 0.29p.Aptamer currently has 1,920,000,000 shares in issue. The market capitalisation of Aptamer is £5,376,000. Aptamer has a price to earnings ratio (PE ratio) of -1.87. This morning APTA shares opened at 0.29p |
Posted at 06/11/2024 07:04 by affc21 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Commercial Trading Update Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to provide an update on contracts signed since its financial year ended 30 June 2024. Aptamer has secured new contracts worth up to £471,000 continuing the positive commercial traction achieved during the last quarter of the previous financial year. These contracts include multiple agreements, including two from top 20 and one from a top 5 global pharmaceutical companies, totalling up to £340,000. These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics. A significant proportion of these deals involve repeat customers who are advancing Aptamer's binders within their internal pipelines, with some signalling intent for long-term licensing revenues. This ongoing traction highlights Aptamer's role in supporting key industry players and reinforces our position as a key player in the market.These new contracts illustrate Aptamer's increasing commercial traction and the Group's ability to secure repeat business from top pharmaceutical companies. Aptamer now has booked revenue contracts of up to c. £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4.0m as of today.Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit. We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of 7 months left in the financial year. Revenue generation and increased income from licensing form a pivotal component of the Group's strategy to deliver shareholder value and I look forward to updating you on future contracts and key project updates."? - Ends -? |
Posted at 17/10/2024 09:33 by someuwin 17 October 2024Aptamer Group plc ("Aptamer", the "Company" or the "Group") Notice of Results and Investor Presentation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2024 on Tuesday, 22 October 2024. The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer will provide a live presentation relating to the full year results via Investor Meet Company on Tuesday, 22 October 2024 at 2:00 pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via: hxxps://www.investor Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited. |
Posted at 03/7/2024 06:34 by gepetto100 Aptamer Group plc("Aptamer", the "Company" or the "Group")Agreement to explore Optimer vehicles for targeted delivery of siRNA- New collaboration will evaluate Aptamer's fibrotic liver delivery vehicles with siRNA Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Following the encouraging results achieved to-date with Aptamer's fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA. Under the agreement, AstraZeneca will provide an siRNA to be trialled with Aptamer's Optimer-based delivery vehicle for fibrotic liver cells. Aptamer Group will conduct in-house experimental work to assess the effectiveness of this delivery vehicle with the AstraZeneca's siRNA. Upon success, Aptamer Group will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca. Delivery of siRNA to precise cell types and tissues with successful cell internalisation remains a significant challenge for the wider therapeutic application of the technology. Despite this limitation, the siRNA market was still valued at over $13 billion in 2023. Optimer technology could represent a paradigm shift in the targeted delivery of siRNA molecules, due to the high levels of selectivity, high affinity and simple conjugation of siRNA payloads, offered using Optimer delivery systems as non-viral vectors. If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are really excited to work with AstraZeneca to evaluate and optimise our Optimer delivery vehicles."Partnershi |
Posted at 24/6/2024 06:12 by multibagger Good morning all :)Another excellent RNS and further proof that a number of contracts being signed and many more to come ! RNS Number : 4897T Aptamer Group PLC 24 June 2024 Aptamer Group Announces New Contracts Worth £235,000 for Optimer Development - Contract with top five pharma partner for IHC reagents - Contract to develop Optimer for life science kits with royalty-bearing licence upon commercialisation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce the signing of two significant contracts for the development of Optimer binders, with a combined total value of up to £235,000. The first contract, valued at up to £175,000, is with a top five pharmaceutical company. As part of this contract, Aptamer will develop Optimer binders for use in immunohistochemistry (IHC) applications. There is potential for the Optimer binders to utilise the Company's recently patented Optimer-Fc platform to deliver advanced IHC reagents for improved performance and use in automated IHC workflows. Following development, the binders could be integrated into companion diagnostics or as critical reagents to support the top five partner's drug development pipeline, resulting in downstream royalties and/or licencing revenues for Aptamer. This agreement represents the sixth contract with this pharmaceutical partner for Optimer development across multiple applications, highlighting its confidence in the Optimer platform. The second contract, valued at up to £60,000, is with a global provider of specialty enzymes used widely throughout the life sciences sector, in a $9.9bn market, growing at 8.6% CAGR. Aptamer will develop Optimer binders as novel reagents to be incorporated into the partner's life science and diagnostic assay kits. Through a non-exclusive licence for the developed Optimer, Aptamer Group will earn milestone payments upon successful commercialisation and downstream high single digit royalties from the gross sales of all kits containing the developed Optimer. Sales could commence as early as 2025. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "The repeat business from another of our top-five pharma partner validates the power of the Optimer platform to solve intractable problems associated with traditional ligands like antibodies in the area of immunohistochemistry (IHC) and supports our new business and patenting strategy. These smaller royalty bearing agreements to develop Optimer binders aligns with our business model to develop a diversified pipeline of technologies to deliver licence agreements across the life science sector. Unfortunately, due to confidentiality we cannot disclose the name of the partner or any other terms of the deal. Over the past year, the new management team has successfully rebuilt the sales pipeline, and refocused the business to its pre-IPO model which continues to convert to signed deals - with opportunities to generate passive income through licensing and royalty-based deals. I look forward to updating the market on continuing commercial progress and on the continued development of our key assets in delivery vehicles for the Liver Fibrosis, binders for cosmetic applications with Unilever and our ongoing partnership with Neuro-Bio developing a diagnostic for Alzheimer's." - ENDS - |
Posted at 07/6/2024 05:08 by multibagger Good morning timbo003 and all :)Most welcome and love to have your input given your expertise ! As I have said before this is a rapidly evolving M&A space and big pharmas are very keen to build their drug pipelines and gain a strong technological edge. So small/start ups in this space with promising technology or early stage molecules/orphan drug status are being bought up - even if it is to simply deny their competitors the advantage (lest they regret the same) ! In a hypothetical situation, if we are bought for $50m, our share price would be in the region of 13p ! A very long way to go yet, but a couple of licensing deals with pharmas could lead to a not too different scenario for APTA and Drs AT and DB could be offered £7 digit annual salaries apart from stock options in the acquiring pharma. I know it happened with Orchard Therapeutics. I would love to see AT and DB's hard work and efforts come to fruition in this manner - it would be only fair, just and very well deserved IMHO. My rationale for taking a decent stake is that the APTA IP is grossly very undervalued, the scope of potential application is simply massive across a number of sectors, big pharma or Unilever could acquire APTA. At the current share price the upside far outweighs the downside risk, which I am very happy to take. Good luck all :) |
Posted at 29/5/2024 09:10 by multibagger Good morning all :)More TR1 action recently and delighted to some blue in terms of the share price Let's hope the big volume/ ? TR1 sellers are done selling and the share price re-rate can commence. Hopefully the worst is behind us and the tide is turning for APTA :) Director buying will be the icing on the cake, but I guess they are likely to be in a "closed period" which is an unfortunate position to be in when the share price is quite low. A big pharma licensing deal for diagnostics or therapeutic applications or Unilever for FMCG products is likely to set the share price alight - I am biased of course ! Good luck all ! |
Posted at 22/5/2024 07:53 by citys2874 RNSAptamer Group plc ("Aptamer", the "Company" or the "Group") Aptamer and Timser partner to deliver world's first blood test for cervical cancer Agreement for up to £465,000 signed for Optimer development Optimer binders will be developed for use in a cervical cancer blood test Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women's health, with a deal value of up to £465,000. Under the terms of the agreement, Aptamer Group will develop Optimer binders to Timser's patented cervical cancer biomarker panel - a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world's first blood test for cervical cancer, preventing invasive smear tests and delivering earlier, more sensitive diagnostics. Pairs of Optimer binders will be developed to each of the three biomarker proteins that form the unique cervical cancer signature. Timser will receive a licence for the use of the Optimers in its specific test combination, which is patented in 21 countries, including the USA. Cervical cancer is the fourth most common cancer type in women worldwide. Present screening methods rely on invasive and relatively low sensitivity Papanicolaou (PAP) smear tests. The Optimer enabled Timser's diagnostic will allow earlier detection at the precancerous lesion stage, which is associated with increased survival. Use of a blood-based test over traditional PAP smears will offer the potential for increased detection rates by improving uptake due to the less invasive testing method. As Timser expands its diagnostic tests into diverse markets, including low-income countries, the Optimer binders offer advantages to support continued supply and quality. With superior shelf-life and enhanced temperature stability compared to antibodies, Optimer binders facilitate global test distribution without compromising quality or performance. Previous attempts by Timser to develop antibodies to support the test have failed due to issues with antibody batch variability and supply chains. Unlike antibodies, Optimer binders are chemically manufactured, giving consistent quality, with the potential to use multiple manufacturers both locally and globally to prevent supply chain issues. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests." Mercedes Gutierrez, Chief Executive Officer of TIMSER Group: "We are equally excited about this collaboration with Aptamer Group. The potential of Optimer binders to enhance the accuracy and reliability of our cancer diagnostics tests is truly promising. By integrating this advanced technology, we are confident in our ability to overcome the limitations of traditional antibodies and improve the outcomes for patients undergoing cervical cancer screening. We look forward to a successful partnership and to witnessing the impact that this new technology will have for women across the globe." |
Posted at 10/5/2024 06:10 by multibagger Good morning bones698 and all :)Thanks for your observations and as I have said before there are many different ways to make money in the markets and which is an "infinite game" (you can chose when you join or leave the market with no impact on anyone else). The share price fall from 117p to about 0.65p now is very steep and given the nature of RNS announcements coming through, it seems to signal to me a share price price bottom. "Fee for service" is what keeps the lights on at the moment, in the absence of big licensing fees. They seem to be typically 6 figure £ sums and I don't think every such contract income is announced ? We start with £2.1m at 31 Jan 2024 and note that there seems to be about £1.4m of work going through their lab currently, so I assume at least 60% will translate into income, even with a 40% attrition rate. Then there is a further £2.9m sales pipeline some of which can then move into lab production. Cash burn is around £285k per month...so several months cash available without any other income coming in. So though there could well be a fund raise in the future, I don't see it at imminent and I expect the share price to lift gradually with more income generating RNSs coming through. Some holders obviously have had enough and are selling out, but I am new to this share and at this price see it very differently. I am happy to add at these levels and have built up a small pot and let's see how it goes - happy to be a contrarian and an outlier ! Good luck all :) |
Posted at 05/5/2024 13:23 by multibagger Many thanks for your kind perspective and rationale....I am not sure if you have seen this APTA webinar from March 2024 The financial and cash position discussion is from about 9m 20sec onwards..... According to this slide the cash position was actually (better) at £2.1 as of 31st Jan 2024. So some revenues are coming in. Another more recent presentation and Andrew Rapson comes in around 13min 23 sec in with regards to finances Different ways to time the entry into a stock. I am not good at getting the timing right, so I am aim for the "sweet 60%"...in other words I don't expect to buy in the lowest 20% of the share price or be able to sell in the highest 20% of the share price APTA is publicly listed and hence the primary reason is to raise capital and I am sanguine about it. The only question I ask is it for "survival" or is it for "growth" and given how fund raises come about, it is often piggybacked to some excellent RNS news which propels the share price in the short term and allows a placing at a higher share price than previous level. At this time though money is tight, we are able to keep the lights on fwith about £1.3m in the labs (in production) and a £2.9m sales pipeline. I accept that a fund raise is likely to happen in the future but not as early as you predict (based on the evidence above), but the way I see it given we are at around 0.68p, any good news of significance can propel this 200+% in the blink of an eye and I don't want to be chasing the buying then. Good luck - we are all in the market to make money, though our thought processes and methods to get there are different. |
Posted at 05/5/2024 07:07 by multibagger Good morning timbo003 and all !Hope you are having some great weather ! Many thanks for your kind words and warm welcome to your thread and for sharing your career earned insights from big Pharma R&D and Consumer care ! These are priceless to the likes of me :) There was recent news (below) from Boehringer which is very heartening, as we have been told that APTA are also working in this area of MASH..one pharma licensing deal can be absolutely transformational for APTA and there seem to be number of irons in the fire. To me it is not a question of if, but when....that a big RNS lands and the share price could do several hundred % in a short time as we are starting from a very low share price Anyone remember NCYT during the Covid years going from 6p to £12 plus in a very short span of time ? I fully agree with you that though some may view APTA with "suspicion" in terms of need to raise funds in the near future, the funding landscape is changing and evolving. There are other ways in which funds could be raised if needed and the likes of Unilever will not want to lose a "strategic technology edge" to the likes of P&G, L'oreal or Biersdorf. Take for example the recent news from a Japanese pharma consortium looking at an Incubator Fund. From the company power point presentations and logos of partners advertised, I guess we have worked with Takeda in the past and may be doing so currently ? Another company is called Orchard Therapeutics which recently announced breakthrough therapy for an orphan condition MLD and is reputed to being sold at over $4 million per patient per year....precision medicine solutions are very expensive. So IMHO the market is grossly mis-pricing the value of precision medicine therapies in a company like APTA and they seem to be working with top 5, top 10 and top 15 pharmas already. I believe that the upside is potentially huge and will act accordingly ! Good luck all :) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
